Category Archives: Biotechnology

Marc Beer’s Renovia Launches New Product For Pelvic Floor Disorder

Marc Beer likes his biotechnology and pharmaceuticals very much that he dedicated almost all his career in contributing to the two industries. Marc founded ViaCell, a biotechnology company that specializes in the collection, preservation, and development of the umbilical cord blood stem cells. He stayed in the company for seven years to see through it that it would end up in success. The ViaCell was acquired by PerkinElmer in 2007.


He is also the Founding Chairman of the BOD for Good Start Genetics, Inc. He is also the founding chairman of Minerva Neurosciences Inc and a member of Miami University Business Advisory Council. After 25 years in walking to the path of biotechnology and pharmaceuticals, Marc founded the Renovia with Ramon Iglesias, MD and Yolanda Lorie. Renovia was founded on August 2016 and since then managed to get a Series B funding and a venture debt worth of $42 million for a new product. The product focuses on treating pelvic floor disorders. The Longwood Fund made the series B round funding possible.


Pelvic Floor Disorders are ailments that affect the pelvic floor, which contains muscles, ligaments, and tissues that support the urinary and reproductive system in females. One example of the Pelvic Floor Disorder is the urinary incontinence, which affects 250 million women globally. Leva’s main target is to help women who suffer from Pelvic Floor Disorders. According to UChicago Medicine, almost one-quarter of women have pelvic floor disorders. Hopefully, Leva can also bring awareness about the condition to better diagnose and treat affected women.


One of the Pelvic Floor Disorder treatments developed by Renovia is the Leva, which aims to strengthen the pelvic floor muscles and rehabilitating the weak ones via technology using Bluetooth and smartphone. The product uses interactive visualization and aims to fix urinary incontinence without surgery or related medication.


The funding from the Series B round and the venture debt is expected to go to toward the development and testing of four new products which focuses on therapeutic and diagnostic tasks. These four products include the Leva device.


Beer stated that he and the folks from Renovia are thrilled and grateful at the same time for the investors who share their vision, and that is to have a better diagnostic and treatment of millions of women affected by the disorder. In addition to that statement, Beer expected that by combining their sensor technologies with a digital health platform will be a good combination for greater knowledge about pelvic floor disorders.


The company answered a lot of questions about their products. But they did not respond to questions about the investment. As reported by Bizjournals, they did not also respond when asked about the seeming pipeline model of their products. Learn more:


Marc Beer Appreciates The Additional Round Of Funding For Renovia

New Business

In April of this year Renovia’s first product Leva was approved by the Food and Drug Administration. One of the participants in Marc Beer’s funding included the Longwood Fund. Longwood Fund is an investor that primarily focuses on issues I healthcare. The company became a backer very early in Renovia’s start. Series B round was led by Acension Ventures of Missouri and the Perceptive Advisers of New York. All of the support Marc Beer received is helping to fund testing and development of four of Renovia’s products. Beer’s goal is for Renovia to create the next generation of Leva. Learn more:


Thankful For The Funding

When Marc Beer announced the funding he received, he gave a special thanks to a bunch of star investors in health care. Renovia’s sensor technologies will be combined with a digital health system. Marc Beer will be the head of the development process. He believes the combination of advanced technology will provide valuable information for customers that can bring on new choices for treatment.


Fighting Pelvic floor Disorders

With the growing awareness and understanding of pelvic floor disorders, long-term health care costs can be reduced. Renovia has committed to strengthening the pelvic floor muscles to overall restore pelvic health. The goal of Renovia ultimately gives access to choices that allow patients to recover the control of pelvic floor muscles.


About Marc Beer

Marc Beer holds a B.S. in business from Miami University. He earned his degree back in 1987. He has been a business leader that aimed to help the public ever since. He has been a consultant for OvalScience, which is an organization that researches treatment choices to fight infertility. He has also served on the board of directors for the Joe Andruzzi Cancer Foundation. This foundation helps families and patients that are facing financial struggles due to the battle with cancer.


What’s So Special About His Leadership?

Marc Beer’s outstanding leadership ability in business is what places him as an innovator that seeks to find solutions to important matters. He worked with Ramon Iglesias, M.D. and Yolanda Lorie, to create Renovia. They founded the company in 2016. It is Marc Beer’s vision and energy that he brings to ventures and the clients they have. He has a remarkable ability to find a need for a company to address urgent matters. That’s why he wanted to start Renovia. It’s this same urgency he saw that made him create ViaCell. ViaCell is now a public company that uses biotechnology that focuses on the collection and preservation and development of stem cells from umbilical cords. It only took him seven years to grow the company into a major enterprise. Follow Marc Beer on LinkedIn


Marc Beer’s Renovia Completes Series B Financing With Over $42 Million

Mark Beer’s Renovia Inc. announced in late August of 2018 the close of over $42 million in financing, which includes $10 and $32.3 million in venture debt and Series B equity respectively. The company focuses on discovering and delivering digital therapeutic as well as devices for women who suffer from pelvic floor disorders. The financing will accelerate the clinical research, and the development and launch of a new digital therapeutic device targeted towards pelvic floor disorders. In addition, the proceeds will be used to support the company’s corporate development as well as future commercial launches.


Renovia was established by Marc Beer alongside Yolanda Lorie and Ramon Iglesias, MD in August of 2016. Marc Beer holds a BS degree from the Miami University and has over 25 years of experience when it comes to development and commercialization in areas such as biotechnology and pharmaceuticals. Beer acts as the company’s Chairman and Chief Executive Officer. Prior to co-founding Renovia, Beer held various executive roles for companies such as ViaCell (where he served as the Chief Executive Officer) and Erytech Pharma, and Genzyme. Learn more:


Renovia was founded to develop and commercialize items that can be used for better first-line diagnosis as well as treatment in order to improve the quality of life of millions of women who suffer from pelvic floor disorders. The company’s technology enables treatment through precise visualization of movement in the pelvic area in real time during the training of the pelvic floor muscle, while monitoring progress and usage over time. The company is in pursuit of scalable as well as cost-effective care for pelvic floor disorders provided via digital health.


Marc Beer commented on the Series B financing stating that the company is thrilled to have the support of leading investors in the healthcare industry who are sharing their vision to better diagnose, treat and improve the lives of women affected by pelvic floor disorders. He also expressed excitement over the participation of 3 integrated health networks with whom Renovia can partner. Additionally, he stated that the combination of Renovia’s proprietary and innovative sensor technologies and form factors with a platform designed for digital health will provide customers important data which can inform about new treatment options and drive greater understanding of pelvic floor disorders – which can ultimately lower healthcare costs.


Marc Beer considers that the funding recognizes the value of Renovia’s innovative digital diagnostic and therapeutic product pipeline that they plan to bring to pelvic floor disorders’ treatment – including urinary incontinence. Urinary incontinence is a common condition across the world and it affects about 250 million women. The company has been committed to the development of a product pipeline that has the therapeutic and diagnostic potential which can end up having a profound positive impact on the lives of women affected by the disorder.